SEARCH

SEARCH BY CITATION

References

  • 1
    Calais Da Silva F, Marquis P, Deschaseaux P, Gineste JL, Cauquil J, Patrick DL. Relative importance of sexuality and quality of life in patients with prostatic symptoms. Eur Urol 1997; 31: 27280.
  • 2
    Robertson C, Link CL, Onel E et al. The impact of lower urinary tract symptoms and comorbidities on quality of life: the BACH and UREPIK studies. BJU Int 2007; 99: 34754.
  • 3
    Fourcade RO, Théret N, Taïeb C. Profile and management of patients treated for the first time for lower urinary tract symptoms/benign prostatic hyperplasia in four European Countries. BJU Int 2008; 101: 11118.
  • 4
    Barkin J, Roehrborn CG, Siami P et al. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial. BJU Int 2009; 103: 91926.
  • 5
    Roehrborn CG, McConnell JD, Barry MJ et al. AUA guideline on the management of benign prostatic hyperplasia (BPH) 2003. Updated 2006. Available at: http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines.cfm?sub=bph [accessed 5th February 2010].
  • 6
    De La Rosette JJ, Alivizatos G, Madersbacher S et al. EAU guidelines on benign prostatic hyperplasia (BPH). Eur Urol 2001; 40: 25663.
  • 7
    Watson V, Ryan M, Brown CT, Barnett G, Ellis BW, Emberton M. Eliciting preferences for drug treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol 2004; 172: 23215.
  • 8
    Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, De La Rosette JJ. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 2004; 46: 54754.
  • 9
    O’Leary MP, Roehrborn C, Andriole G, Nickel C, Boyle P, Höfner K. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor. BJU Int 2003; 92: 2626.
  • 10
    Bruskewitz R, Girman CJ, Fowler J et al. Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Urology 1999; 54: 6708.
  • 11
    McVary KT. Alfuzosin for symptomatic benign prostatic hyperplasia: long-term experience. J Urol 2006; 175: 3542.
  • 12
    Lepor H, Williford WO, Barry MJ, Haakenson C, Jones K. The impact of medical therapy on bother due to symptoms, quality of life and global outcomes, and factors predicting response. J Urol 1998; 160: 135867.
  • 13
    Siami P, Roehrborn CG, Barkin J et al. Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design. Contemp Clin Trial 2007; 28: 7709.
  • 14
    Roehrborn CG, Siami P, Barkin J et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008; 179: 61621.
  • 15
    Roehrborn CG, Siami P, Barkin J et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010; 57: 12331.
  • 16
    Barry MJ, Williford WO, Chang Y et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients. J Urol 1995; 154: 17704.
  • 17
    Chatelain CH, Denis L, Foo JK et al. (2001) Recommendations of the International Scientific Committee: evaluation and treatment of lower urinary tract symptoms (LUTS) in older men. In: ChatelainC, DenisL, FooKT, KhouryS, McConnellJ, eds. Fifth International Consultation on Benign Prostatic Hyperplasia. UK: Health Publications, pp. 51934.
  • 18
    Black L, Grove A, Morrill B. The psychometric validation of a US English satisfaction measure for patients with benign prostatic hyperplasia and lower urinary tract symptoms. Health Qual Life Outcomes 2009; 7: 55.
  • 19
    McConnell JD, Roehrborn CG, Bautista OM et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 238798.